Pediatric Migraine Diagnosis and Management

Diagnosis

• The American Academy of Neurology recommends that pediatric migraine diagnosis relies primarily on clinical history using modified ICHD criteria, requiring at least 5 attacks lasting 2-72 hours, with at least 2 of the following: bilateral or unilateral location, pulsating quality, moderate-to-severe intensity, or aggravation by routine physical activity 1, 2
• Attacks are typically shorter in duration (2-72 hours versus 4-72 hours in adults) 1
• Headache is more often bilateral rather than unilateral 1, 3
• Pulsating quality is less common than in adults 1
• Gastrointestinal symptoms (nausea, vomiting) are prominently featured and may dominate the presentation 1
• Onset typically occurs at or around puberty, with prevalence increasing through adolescence 1, 3, 4

Acute Treatment

• The American Academy of Neurology recommends ibuprofen at weight-appropriate dosing as the first-line medication for acute pediatric migraine 1, 2, 3, 4
• Bed rest alone may suffice for children with short-duration attacks 1, 3, 4
• Nasal spray formulations of sumatriptan or zolmitriptan are most effective among triptans for adolescents aged 12-17 years 1

Preventive Treatment

• The American Academy of Neurology recommends preventive therapy in patients adversely affected on ≥2 days per month despite optimized acute treatment 1
• Propranolol, amitriptyline, and topiramate are used for preventive treatment, although their effectiveness in children and adolescents has not been proven in clinical trials due to high placebo response 1, 3, 4
• Propranolol (80-160 mg daily) is specifically recommended for pediatric migraine prevention and is appropriate for patients with comorbid hypertension or anxiety 5

Critical Management Principles

• Active involvement from family members and teachers is necessary for clinical management in children and young adolescents, requiring education of both 1
• Patients and families must be educated on lifestyle factors, migraine triggers, and avoiding overuse of acute medication to prevent medication overuse headache 2
• If acute medication provides insufficient pain relief, referral to specialist care is indicated 1
• Specialist referral is indicated for patients with chronic migraine 3, 4

Selecting Antimigraine Prophylaxis in Children

Introduction to Prophylaxis

• The American Academy of Neurology recommends starting with propranolol (80-160 mg daily), amitriptyline (10-100 mg at night), or topiramate (50-100 mg daily) as first-line options for pediatric migraine prophylaxis, with the critical caveat that families must understand these medications showed similar efficacy to placebo in many pediatric trials 6, 7, 8

First-Line Prophylactic Agents

• Propranolol dosing is 80-160 mg oral daily in long-acting formulations, with contraindications including asthma, cardiac failure, Raynaud disease, atrioventricular block, and depression 9, 10
• Amitriptyline dosing is 10-100 mg oral at night, with enhanced efficacy when combined with cognitive behavioral therapy, and contraindications including age <6 years, heart failure, co-administration with monoamine oxidase inhibitors and SSRIs, and glaucoma 6, 7, 8, 9, 10
• Topiramate dosing is 50-100 mg oral daily, with critical warnings including teratogenicity, requiring effective contraception and folate supplementation in adolescent females of childbearing potential, and contraindications including nephrolithiasis, pregnancy, lactation, and glaucoma 6, 7, 8, 9, 10

Monitoring and Adjustment

• Evaluate response at 2-3 months after initiation or dose change, using headache calendars to track attack frequency, severity, and disability 9, 10
• Define success as ≥50% reduction in attack frequency, and if first agent fails, try another from the first-line options rather than declaring treatment failure prematurely 9

Special Considerations

• The American Academy of Neurology recommends that adolescent females with migraine with aura should not be prescribed combined hormonal contraceptives due to stroke risk 9, 10
• Lifestyle modifications and trigger avoidance remain foundational, and acute medication should be optimized (ibuprofen first-line) before adding prophylaxis 6, 7

Preventive Migraine Medication Guidelines for Adolescents

Indications for Initiating Preventive Therapy

• Preventive treatment should be considered when migraine attacks occur on ≥ 2 days per month and cause functional impairment despite optimized acute therapy, or when medication overuse is present. 11

Counseling on High Placebo Response

• Clinicians must inform patients and families that placebo responses have been comparable to active medications in multiple pediatric migraine trials, underscoring the importance of non‑pharmacologic strategies alongside any drug choice. [11][12][13][14]

First‑Line Preventive Options

Amitriptyline Combined with Cognitive‑Behavioral Therapy (CBT)

• Adding CBT to amitriptyline improves preventive efficacy compared with amitriptyline alone. 11
• Common adverse effects include sedation, dry mouth, weight gain, and constipation. 13

Topiramate

• Topiramate carries a teratogenic risk in adolescent females; mandatory counseling on effective contraception and folate supplementation is required for all patients of childbearing potential. 11
• Typical side‑effects are cognitive slowing, paresthesias, weight loss, kidney‑stone formation, and metabolic acidosis. 12

Propranolol

• (No specific cited data on efficacy or dosing were provided in the cited references.)

Special Considerations for Females of Child‑Bearing Potential

• When a preventive agent is needed for a female of child‑bearing potential, topiramate may be used only with documented contraception use and folate supplementation; otherwise, amitriptyline + CBT or propranolol are preferred. 11
• The American Academy of Neurology advises against using divalproex/valproate in this population because of teratogenicity and a lack of superior efficacy, and it recommends folate supplementation solely for topiramate, not valproate. 11

Optimization of Acute Migraine Treatment (Before Adding Prevention)

• If ibuprofen is insufficient, consider a sumatriptan/naproxen oral combination, zolmitriptan nasal spray (5 mg), sumatriptan nasal spray, or rizatriptan orally disintegrating tablet as first‑line acute options. 11
• Patients should be instructed to treat attacks at the earliest sign of headache to maximize acute medication effectiveness. 11

Monitoring, Success Criteria, and Medication Overuse Prevention

• Use headache diaries to objectively track attack frequency, severity, and disability.
• Define treatment success as a ≥ 50 % reduction in migraine attack frequency after a 2–3 month trial at therapeutic doses. 11
• Educate families that overuse of acute medications (≥ 15 days/month for NSAIDs or ≥ 10 days/month for triptans) can exacerbate headache frequency and severity. 11

Contraindicated or Discouraged Medications

• Divalproex/valproate should be avoided in adolescent females of child‑bearing potential due to teratogenic risk and insufficient evidence of superiority over other preventive agents. 11